A Cannabinoid Receptor Agonist is a substance that activates the cannabinoid receptors in the body. These receptors are part of the endocannabinoid system, which plays a role in various physiological processes. When a cannabinoid receptor agonist binds to these receptors, it triggers a series of biochemical reactions that modulate neurotransmission and cellular signalling. The mechanism of action of a cannabinoid receptor agonist involves mimicking the effects of endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol, by binding to and activating the cannabinoid receptors. This activation can lead to a wide range of effects, including pain relief, modulation of appetite, regulation of mood, and immune response modulation. cannabinoid receptor agonists have been studied and used in the treatment of various medical conditions. These include chronic pain, neuropathic pain, spasticity associated with multiple sclerosis, nausea, and vomiting in cancer chemotherapy, appetite stimulation in conditions like HIV/AIDS and cancer, and epilepsy.
The growth drivers of the Cannabinoid Receptor Agonist stimulator market include increasing acceptance of medical cannabis and cannabinoids for therapeutic purposes, as well as the expanding legalization of cannabis in various regions, which opens up new opportunities for research, development, and commercialization of cannabinoid-based medications and treatments. Companies such as Viatris, Jazz, Tetra Bio-Pharma, Ipsen, Alternavida, Avicanna, Axim Biotech, Bausch Health, Bionorica, Botanix Pharma, Cann Pharma, FSD Pharma currently cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Jazz is one such company that is currently conducting a clinical trial of the drug Cannabidivarin(GWP42006) for the treatment of epilepsy.
Key Developments
In January 2023, Jazz Pharmaceuticals received a NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of Tuberous sclerosis in the UK.
In March 2022, Benuvia Therapeutics pursued 505(b) fast-track approval with the US FDA for Investigational New Drugs for its dronabinol oral solution in Alzheimer's disease.
Approved Cannabinoid Receptor Agonist molecules
- Dronabinoloral
- Epidiolex (cannabidiol)
- Sativex (nabiximols)
- Cesamet (nabilone)
Cannabinoid Receptor Agonist Pipeline Molecules
- Acetazolamide/Tetrahydrocannabinol (IHL-42X)
- Dronabinol(BX-1)
- Qixleef(inhaled medical cannabis)
- Cannabidivarin(GWP42006)
- Dronabinol/Palmitoylethanolamide (SCI-110)
- Micro-palmitoylethanolamide(FSD201)
- Avi-Dekel(cannabisoil20:1)
- CannabidiolTechnosphere(cannabidiol inhalation powder)
- Syndros(dronabinol oral solution)
- Oraldelta-9-tetrahydrocannabinol/cannabidiol (oral CBD/THC)
- BTX-1801
- CanChewRx(cannabidiolchewinggum)
- Caumz(cannabidiol/delta 9 tetrahydrocannabinol)
- Hope(tetrahydrocannabinol/cannabidiol)
- VSN16R
- ZYN001
- Cannabidiol 3% Cream (AVCN583601)
- Cannabidiol oil capsules
- cannabidiol/tetrahydrocannabinol (EP1)
- cannabisorallydisintegratingtablet(MGC-ODT)
- tetrahydrocannabinol/cannabidiol (TIL-TC150)
- vaporized cannabis
Clinical Activity and Development of Cannabinoid Receptor Agonist
In the cannabinoid receptor agonist space, more than 20 companies are focusing on approximately 94 disease indications and right now about 3520 clinical trials are being conducted in this category of drugs. For instance,
In April 2023, GW Pharmaceuticals presented long-term efficacy and adverse events data from the phase III open-label extension GWPCARE6 trial in tuberous sclerosis at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
In October 2022, Pleo Pharma started a phase II, multicenter, randomized, double-blind, multiple-dose, placebo-controlled clinical trial of two doses of PP-01 (Nabilone & Gabapentin) for the mitigation of cannabis withdrawal symptoms, whose estimated study completion date is September 2023.
|
ProductName |
Total Studies |
|
Acetazolamide/tetrahydrocannabinol (IHL-42X) |
6 |
|
Dronabinol (BX-1) |
6 |
|
Qixleef (inhaledmedicalcannabis) |
5 |
|
Cannabidivarin (GWP42006) |
5 |
|
Dronabinol/palmitoylethanolamide (SCI-110) |
5 |
|
Micro-palmitoylethanolamide (FSD201) |
4 |
|
Avi-Dekel (cannabisoil20:1) |
3 |
|
CannabidiolTechnosphere (cannabidiolinhalationpowder) |
3 |
|
Syndros (dronabinoloralsolution) |
2 |
|
Oral delta-9-tetrahydrocannabinol/cannabidiol (oral CBD/THC) |
2 |
|
BTX-1801 |
1 |
Target Indication Analysis of Cannabinoid Receptor Agonist
The cannabinoid receptor agonists are primarily used to treat chronic pain, neuropathic pain, spasticity associated with multiple sclerosis, nausea, and vomiting in cancer chemotherapy, appetite stimulation in conditions like HIV/AIDS and cancer, and epilepsy. cannabinoid receptor agonists also help to prevent CNS disorders. For instance, Dronabinol is one drug that is used for CNS disorders in adult patients. In the treatment of neuralgia, sclerosis, nausea, and neurologic manifestations cannabinoid receptor agonist Cesamet(Nabilone) by Viatris is used widely. Through research and development, the indications in which cannabinoid receptor agonists can be used are getting expanded. Trials of Sativex (Nabizimois) are being conducted for the treatment of diseases like squamous cell carcinoma and glioblastoma.
Regional Analysis of Cannabinoid Receptor Agonist
Cannabinoid Receptor Agonist Market
The global cannabinoid receptor agonist market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US and UK regional market for Cannabinoid Receptor Agonists is experiencing significant growth. With the legalization of medical and recreational cannabis in several states, there is a growing demand for cannabinoid-based medications and treatments. The market is driven by factors such as increasing acceptance of cannabis, expanding research and development activities, and the rising prevalence of conditions that can potentially be managed with cannabinoid receptor agonists. The United States, being a frontrunner in the healthcare industry, holds a significant share of the market. The global sales of Epidiolex of Jazz Pharmaceuticals in the financial year of 2021-22 were $736.4 million. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for cannabinoid receptor agonists. These countries are increasingly adopting cannabinoid receptor agonists due to their efficacy and potential to improve patient outcomes. On the other hand, the cannabinoid receptor agonist market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the cannabinoid receptor agonist market. These countries are characterized by a well-established healthcare infrastructure, strategic collaborations between pharmaceutical companies, and growing awareness about cannabinoid application in healthcare, which further contributes to the opportunity in this market.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
The approved molecule of cannabinoid receptor agonists is Dronabinol oral, Epidiolex (cannabidiol), Sativex (nabiximols), and Cesamet (nabilone)
The growth drivers of the Cannabinoid Receptor Agonist stimulator market include increasing acceptance of medical cannabis and cannabinoids for therapeutic purposes, as well as the expanding legalization of cannabis in various regions, which opens up new opportunities for research, development, and commercialization of cannabinoid-based medications and treatments
The major players in this space are Tilray, Jazz, Tetra Bio-Pharma, Ipsen, Alternavida, Avicanna, Axim Biotech, and Bausch Health.
The key restraints of the cannabinoid receptor agonist stimulator market include the complexity and variability of allergic diseases, which make it challenging to develop universally effective treatments, and the potential for adverse effects associated with cannabinoid receptor agonist-targeted therapies. Additionally, the high cost of research and development, as well as the regulatory requirements for approval of new therapies, can pose barriers to market entry for cannabinoid receptor agonist stimulators.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Tilray
- Jazz
- Tetra Bio-Pharma
- Ipsen
- Alternavida
- Avicanna
- Axim Biotech
- Bausch Health
- Bionorica
- Botanix Pharma
- Cann Pharma
- FSD Pharma
- Generic mfg.
- Incannex
- Insys Therap
- LTS Lohmann Therapy Systems
- OWC Pharma
- Receptor Life Sci
- SciSparc
- The Children’s Hospital of Philadelphia
- Tikun Olam Cannbit Pharma
- University College London
- Viatris
- Zelira
- Zynerba